I am a healthcare professional

Notice


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.


Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.


By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


Cookies


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.


You can find out more about cookies by browsing our Privacy Policy.

 

For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Roche and Genentech at

MDS 2022

-
Coming soon

Sign up or login to unlock the full suite of MEDICALLY features

Independent content
Oct 21 / Springer Healthcare
MDS 2022: In-depth report
This MDS 2022 in-depth report provides an overview of advances in the diagnosis and treatment of Parkinson’s disease.

Sign up or login to unlock the full suite of MEDICALLY features

Sep 15 / Roche and Genentech
Exploratory delayed-start analysis of PASADENA evaluating the efficacy of prasinezumab on motor progression and motor complications in early-stage Parkinson's disease
Prasinezumab is a humanised monoclonal antibody designed to target aggregated alpha-synuclein and slow PD progression. PASADENA is a multicentre, randomised, double-blind, placebo-controlled study evaluating the efficacy of prasinezumab in participants with early PD. This study used an exploratory delayed-start analysis of Part 2 (Week 104) PASADENA to evaluate the effect of prasinezumab on motor progression and motor complications.

Sign up or login to unlock the full suite of MEDICALLY features

Sep 15 / Roche and Genentech
Improving the design of clinical trials in early-stage Parkinson’s disease by using the estimand framework
The estimand treatment effect is supported by the new International Council for Harmanization E9 (R1) addendum on Estimands and Sensitivity Analyses in Clinical Trials to define objectives of clinical trials. Clinical trials in Type 2 diabetes are now designed using this estimand framework. This study aims to show how the estimand framework can be used to improve the design of clinical trials testing treatments in early-stage PD.

Sign up or login to unlock the full suite of MEDICALLY features